The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Patients and Methods
2.1. Study Populations and Data Collection
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
BC | bladder cancer |
BCG | bacillus Calmette-Guérin |
COVID-19 | coronavirus-19 |
EAU | European Asscociation of Urology |
EORTC | European Organization for Research and Treatment of Cancer |
NMIBC | nonmuscle invasive bladder cancers |
MIBC | muscle invasive cancers |
RC | radical cystectomy |
TURB | transurethral resection of the bladder |
UTUC | upper tract urothelial cancer |
WHO | World Health Organization |
References
- Misra-Hebert, A.D.; Jehi, L.; Ji, X.; Nowacki, A.S.; Gordon, S.; Terpeluk, P.; Chung, M.K.; Mehra, R.; Dell, K.M.; Pennell, N.; et al. Impact of the COVID-19 Pandemic on Healthcare Workers’ Risk of Infection and Outcomes in a Large, Integrated Health System. J. Gen. Intern. Med. 2020, 35, 3293–3301. [Google Scholar] [CrossRef]
- Byrnes, M.E.; Brown, C.S.; De Roo, A.C.; Corriere, M.A.; Romano, M.A.; Fukuhara, S.; Kim, K.M.; Osborne, N.H. Elective Surgical Delays Due to COVID-19: The Patient Lived Experience. Med. Care 2021, 59, 288–294. [Google Scholar] [CrossRef]
- Petrova, D.; Redondo-Sánchez, D.; Rodríguez-Barranco, M.; Ruiz, A.R.; Catena, A.; Garcia-Retamero, R.; Sánchez, M. Physical comorbidities as a marker for high risk of psychological distress in cancer patients. Psycho Oncol. 2021. [Google Scholar] [CrossRef] [PubMed]
- Liang, W.; Guan, W.; Chen, R.; Wang, W.; Li, J.; Xu, K.; Li, C.; Ai, Q.; Lu, W.; Liang, H.; et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020, 21, 335–337. [Google Scholar] [CrossRef]
- Mandala, M.; Lorigan, P.; De Luca, M.; Bianchetti, A.; Merelli, B.; Bettini, A.C.; Bonomi, L.; Nahm, S.; Vitale, M.G.; Negrini, G.; et al. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: An observational prospective study. J. Immunother. Cancer 2021, 9, e001694. [Google Scholar] [CrossRef] [PubMed]
- Lee, L.Y.W.; Cazier, J.-B.; Angelis, V.; Arnold, R.; Bisht, V.; Campton, N.A.; Chackathayil, J.; Cheng, V.W.; Curley, H.M.; Fittall, M.W.; et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet 2020, 395, 1919–1926. [Google Scholar] [CrossRef]
- Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef] [PubMed]
- Jacob, L.; Loosen, S.; Kalder, M.; Luedde, T.; Roderburg, C.; Kostev, K. Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany. Cancers 2021, 13, 408. [Google Scholar] [CrossRef]
- Roscigno, M.; Naspro, R.; Piccichè, A.; Muttin, F.; Angiolilli, D.; Deiana, G.; Pezzoli, F.; Da Pozzo, L.F. A Snapshot from the Department of Urology in Bergamo Evaluating the Timeline of the SARS-CoV-2 Outbreak: Which Patients Are We Missing? Eur. Urol. Focus 2020, 6, 1120–1123. [Google Scholar] [CrossRef]
- Quaquarini, E.; Saltalamacchia, G.; Presti, D.; Caldana, G.; Tibollo, V.; Malovini, A.; Palumbo, R.; Teragni, C.M.; Balletti, E.; Mollica, L.; et al. Impact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic in Lombardy (Italy). Cancers 2020, 12, 2941. [Google Scholar] [CrossRef]
- Kutikov, A.; Weinberg, D.S.; Edelman, M.J.; Horwitz, E.M.; Uzzo, R.G.; Fisher, R.I. A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann. Intern. Med. 2020, 172, 756–758. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gravas, S.; Fournier, G.; Oya, M.; Summerton, D.; Scarpa, R.M.; Chlosta, P.; Gkialas, I.; Xie, L.-P.; Rasyid, N.; Bolton, D.; et al. Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines. Eur. Urol. Focus 2020, 6, 1104–1110. [Google Scholar] [CrossRef] [PubMed]
- Statistiken. Available online: http://www.statistik.at/web_de/statistiken/index.html (accessed on 2 April 2021).
- Wallis, C.J.; Novara, G.; Marandino, L.; Bex, A.; Kamat, A.M.; Karnes, R.J.; Morgan, T.M.; Mottet, N.; Gillessen, S.; Bossi, A.; et al. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur. Urol. 2020, 78, 29–42. [Google Scholar] [CrossRef]
- Sylvester, R.J.; van der Meijden, A.P.; Oosterlinck, W.; Witjes, J.A.; Bouffioux, C.; Denis, L.; Newling, D.W.; Kurth, K. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur. Urol. 2006, 49, 466–477. [Google Scholar] [CrossRef]
- Lopez-Beltran, A.; Montironi, R. Non-invasive urothelial neoplasms: According to the most recent WHO classification. Eur. Urol. 2004, 46, 170–176. [Google Scholar] [CrossRef] [PubMed]
- Thomas, F.; Noon, A.P.; Rubin, N.; Goepel, J.R.; Catto, J.W. Comparative Outcomes of Primary, Recurrent, and Progressive High-risk Non–muscle-invasive Bladder Cancer. Eur. Urol. 2013, 63, 145–154. [Google Scholar] [CrossRef]
- Babjuk, M.; Burger, M.; Compérat, E.M.; Gontero, P.; Mostafid, A.H.; Palou, J.; van Rhijn, B.W.; Rouprêt, M.; Shariat, S.F.; Sylvester, R.; et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—2019 Update. Eur. Urol. 2019, 76, 639–657. [Google Scholar] [CrossRef] [PubMed]
- Cumberbatch, M.G.; Foerster, B.; Catto, J.W.; Kamat, A.M.; Kassouf, W.; Jubber, I.; Shariat, S.F.; Sylvester, R.J.; Gontero, P. Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review. Eur. Urol. 2018, 73, 925–933. [Google Scholar] [CrossRef]
- Boeri, L.; Soligo, M.; Frank, I.; Boorjian, S.A.; Thompson, R.H.; Tollefson, M.; Quevedo, F.J.; Cheville, J.C.; Karnes, R.J. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. Eur. Urol. Oncol. 2019, 2, 390–396. [Google Scholar] [CrossRef]
- Russell, B.; Liedberg, F.; Khan, M.S.; Nair, R.; Thurairaja, R.; Malde, S.; Kumar, P.; Bryan, R.T.; Van Hemelrijck, M. A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. Eur. Urol. Oncol. 2020, 3, 239–249. [Google Scholar] [CrossRef]
- Nison, L.; Rouprêt, M.; Bozzini, G.; Ouzzane, A.; Audenet, F.; Pignot, G.; Ruffion, A.; Cornu, J.-N.; Hurel, S.; Valeri, A.; et al. The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: Results from a large collaborative database. World J. Urol. 2012, 31, 69–76. [Google Scholar] [CrossRef]
- Waldert, M.; Karakiewicz, P.I.; Raman, J.D.; Remzi, M.; Isbarn, H.; Lotan, Y.; Capitanio, U.; Bensalah, K.; Marberger, M.J.; Shariat, S.F. A delay in radical nephroureterectomy can lead to upstaging. BJU Int. 2010, 105, 812–817. [Google Scholar] [CrossRef] [PubMed]
- Sundi, D.; Svatek, R.S.; Margulis, V.; Wood, C.G.; Matin, S.F.; Dinney, C.P.; Kamat, A.M. Upper tract urothelial carcinoma: Impact of time to surgery. Urol. Oncol. Semin. Orig. Investig. 2012, 30, 266–272. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ficarra, V.; Novara, G.; Abrate, A.; Bartoletti, R.; Crestani, A.; De Nunzio, C.; Giannarini, G.; Gregori, A.; Liguori, G.; Mirone, V.; et al. Urology practice during the COVID-19 pandemic. Minerva Urol. Nefrol. 2020, 72, 369–375. [Google Scholar] [CrossRef] [PubMed]
- Stensland, K.D.; Morgan, T.M.; Moinzadeh, A.; Lee, C.T.; Briganti, A.; Catto, J.W.; Canes, D. Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. Eur. Urol. 2020, 77, 663–666. [Google Scholar] [CrossRef] [PubMed]
- Przyborowski, J.; Wilenski, H. Homogeneity of Results in Testing Samples from Poisson Series: With an Application to Testing Clover Seed for Dodder. Biometrika 1940, 31, 313. [Google Scholar] [CrossRef]
- Tsibulak, I.; Reiser, E.; Bogner, G.; Petru, E.; Hell-Teutsch, J.; Reinthaller, A.; Weirather, C.; Weiss, T.; Bozsa, S.; Puschacher, B.; et al. Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: An Austrian perspective. Int. J. Gynecol. Cancer 2020, 30, 1667–1671. [Google Scholar] [CrossRef]
- Dinmohamed, A.G.; Visser, O.; Verhoeven, R.H.A.; Louwman, M.W.J.; van Nederveen, F.H.; Willems, S.M.; Merkx, M.A.W.; Lemmens, V.E.P.P.; Nagtegaal, I.D.; Siesling, S. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020, 21, 750–751. [Google Scholar] [CrossRef]
- Kang, H.W.; Kim, W.-J.; Yun, S.J. The role of the tumor microenvironment in bladder cancer development and progression. Transl. Cancer Res. 2017, 6, S744–S758. [Google Scholar] [CrossRef]
- Zieger, K.; Dyrskjøt, L.; Wiuf, C.; Jensen, J.L.; Andersen, C.L.; Jensen, K.M.-E.; Ørntoft, T.F. Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors. Clin. Cancer Res. 2005, 11, 7709–7719. [Google Scholar] [CrossRef] [Green Version]
- Bellmunt, J.; Kim, J.; Reardon, B.; Perera-Bel, J.; Orsola, A.; Rodriguez-Vida, A.; Wankowicz, S.A.; Bowden, M.; Barletta, J.A.; Morote, J.; et al. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non–Muscle-Invasive Bladder Cancer. Cancer Res. 2020, 80, 4476–4486. [Google Scholar] [CrossRef] [PubMed]
- Carrasco, R.; Izquierdo, L.; van der Heijden, A.G.; Lozano, J.J.; Franco, M.; Ingelmo-Torres, M.; Roldan, F.L.; Llorens, M.; Ribal, M.J.; Mengual, L.; et al. Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication. Sci. Rep. 2021, 11, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Shariat, S.F.; Ashfaq, R.; Sagalowsky, A.I.; Lotan, Y. Predictive Value of Cell Cycle Biomarkers in Nonmuscle Invasive Bladder Transitional Cell Carcinoma. J. Urol. 2007, 177, 481–487. [Google Scholar] [CrossRef] [PubMed]
- Robertson, A.G.; Groeneveld, C.S.; Jordan, B.; Lin, X.; McLaughlin, K.A.; Das, A.; Fall, L.A.; Fantini, D.; Taxter, T.J.; Mogil, L.S.; et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur. Urol. 2020, 78, 533–537. [Google Scholar] [CrossRef] [PubMed]
2019 | 2020 | p Value | ||
---|---|---|---|---|
Endoscopic Surgery | Patients No. | 240 | 209 | |
Age | 0.381 † | |||
Mean ± SD/Median (IQR) | 70.2 ± 12.6/72 (25–95) | 71.7 ±10.6/72 (38–92) | ||
Sex | 1.000 * | |||
W (%)/M (%) | 39 (16.3)/201 (83.7) | 34 (16.3)/175 (83.7) | ||
Histology | 0.008 * | |||
No malignancy (%) | 75 (31.3) | 76 (36.4) | ||
pTa (%) | 125 (52.1) | 77 (36.8) | ||
pT1 (%) | 11 (4.6) | 22 (10.5) | ||
CIS (%) | 12 (5) | 12 (5.7) | ||
pT2a (%) | 17 (7.1) | 22 (10.5) | ||
Grade | 0.002 * | |||
No malignancy (%) | 75 (31.3) | 76 (36.4) | ||
Low (%) | 104 (43.3) | 58 (27.8) | ||
High (%) | 61 (25.4) | 75 (35.9) | ||
Radical Cystectomy | Patients No. | 22 | 22 | |
Age | 0.647 † | |||
Mean ± SD/Median (IQR) | 67.6 ± 10.8/66.5 (38–83) | 69.4 ± 9.3/70 (46–86) | ||
Sex | 0.162 * | |||
W (%)/M (%) | 8 (36.4)/14 (63.6) | 3 (13.6)/19 (86.4) | ||
Histology | 0.762 * | |||
pT1 | 1 (4.5) | 2 (9.1) | ||
CIS | 1 (4.5) | - | ||
pT2 | 2 (9.1) | 5 (22.7) | ||
pT3 | 5 (22.7) | 4 (18.2) | ||
pT4 | 2 (9.1) | 2 (9.1) | ||
ypT0 | 6 (27.3) | 5 (22.7) | ||
ypT1 | 1 (4.5) | 3 (13.6) | ||
ypTis | 1 (4.5) | 1 (4.5) | ||
ypT2 | 1 (4.5) | - | ||
ypT3 | 2 (9.1) | - | ||
NAC | 0.763 * | |||
Yes (%)/No (%) | 11 (50)/11 (50) | 9 (40.5)/13 (59.1) | ||
Delay > 3 Months | 1.000 * | |||
Yes (%)/No (%) | 1 (4.5)/21 (95.5) | 2 (9.1)/20 (90.5) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tulchiner, G.; Staudacher, N.; Fritz, J.; Radmayr, C.; Culig, Z.; Horninger, W.; Pichler, R. The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer. Cancers 2021, 13, 1754. https://doi.org/10.3390/cancers13081754
Tulchiner G, Staudacher N, Fritz J, Radmayr C, Culig Z, Horninger W, Pichler R. The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer. Cancers. 2021; 13(8):1754. https://doi.org/10.3390/cancers13081754
Chicago/Turabian StyleTulchiner, Gennadi, Nina Staudacher, Josef Fritz, Christian Radmayr, Zoran Culig, Wolfgang Horninger, and Renate Pichler. 2021. "The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer" Cancers 13, no. 8: 1754. https://doi.org/10.3390/cancers13081754